XTalks

MARCH 19, 2025

Eneboparatide (AZP-3601), an investigational parathyroid hormone 1 receptor (PTH1R) agonist, met its primary endpoint in the CALYPSO Phase III trial, offering new data for adults with chronic hypoparathyroidism. Without proper PTH function, patients may face kidney and bone complications.

Trials 59

Trials Hormones Engineer Licensing 59

XTalks

DECEMBER 13, 2024

The study will assess the drugs effects on body weight, safety and tolerability over a 42-week period. Petrelintide, administered once a week under the skin, targets obesity through its action as an amylin analog, a hormone co-secreted with insulin from the pancreas.

Drugs 102

Drugs Hormones Trials Clinical Trials 102

XTalks

FEBRUARY 5, 2025

a clinical-stage biotech company focused on developing next-gen injectable and oral nutrient-stimulated hormone (NuSH) analog peptides for the treatment of obesity, overweight and related conditions, has priced its initial public offering (IPO) at $18.00 Despite this, the drug remains under watch for further development.

Hormones 59

Hormones Bioavailability Clinical Trials Clinical Trials 59

XTalks

FEBRUARY 21, 2025

This capital will accelerate the companys clinical programs and support its pipeline of investigational drugs aimed at treatments for metabolic diseases like Prader-Willi syndrome (PWS). In the gut, these receptors prompt the release of hormones such as cholecystokinin and GLP-1, which together signal satiety.

Genetics 59

Genetics Hormones Gene Expression Gene 59

XTalks

OCTOBER 25, 2023

This includes the effect of the drug on moderate-to-severe vasomotor symptoms in subgroups based on hormone therapy history from pooled data from two randomized Phase III studies. Subscribe to the Xtalks Life Science Podcast to never miss a new episode.

Life Science 52

Life Science Trials FDA Approval Hormones 52

XTalks

JANUARY 29, 2025

Eli Lilly launched a 75-second TV commercial called Change in November 2024 to promote the companys GLP-1 obesity drug Zepbound (tirzepatide). This month, Zepbound won FDA approval for obstructive sleep apnea (OSA) , making it the first approved drug for the condition.

FDA Approval 71

FDA Approval Drugs Hormones Marketing 71

XTalks

MAY 17, 2023

Astellas Pharma recently announced the US Food and Drug Administration (FDA) approval of their new medication, Veozah (fezolinetant) for the treatment of moderate to severe hot flashes and night sweats due to menopause. Hormone replacement therapy is thought to be one of the most effective treatments for vasomotor symptoms.

Hormones 95

Hormones FDA Approval Drugs Clinical Trials 95

XTalks

MAY 26, 2022

In this episode, Ayesha discussed the FDA approval of Eli Lilly’s diabetes injection Mounjaro (tirzepatide) for the treatment of adults with type 2 diabetes This is a great advancement in the diabetes space as Mounjaro is a first-in-class medicine that targets the activity of two hormones involved in hunger and blood sugar control (GLP-1 and GIP).

Life Science 52

Life Science FDA Approval Hormones Sales 52

XTalks

NOVEMBER 12, 2024

Pancreatic cancer occurs when cells in the pancreas, a vital organ responsible for producing enzymes and hormones, begin to grow uncontrollably. The drug was first approved as a second-line treatment for the cancer in adults whose disease has advanced following treatment with standard chemotherapies.

Research 105

Research FDA Approval Trials Clinical Trials 105

XTalks

JANUARY 9, 2024

The thyroid plays a critical role in the body by producing hormones that regulate metabolism, heart rate and body temperature among others. Types of Thyroid Conditions There are several different thyroid conditions, with each affecting thyroid hormone production or the gland’s structure, leading to a range of health issues.

Hormones 105

Hormones Antibody Trials Production 105

XTalks

MARCH 18, 2025

Hidradenitis suppurativa affecting roughly 1% of the population is a chronic skin condition marked by painful boils and abscesses that can significantly disrupt daily life. As reported by Investors.com , RBC Capital Markets analyst Brian Abrahams stated, The drug did hit on statistical significance and could be a viable entrant.

Trials 59

Trials Clinical Trials Clinical Trials Hormones 59

XTalks

JANUARY 23, 2024

Among these, rare pediatric diseases present unique challenges and opportunities for rare disease drug development. Pediatric growth hormone deficiency (PGHD) is one such condition, affecting a child’s growth and development.

Development 72

Development Hormones Drugs Trials 72

XTalks

APRIL 29, 2022

Eli Lilly announced that its obesity drug tirzepatide has scored favorably in a late-stage clinical trial, with results showing that people who took the drug lost an average of 50 pounds, or 21 percent, of their body weight compared to placebo. percent and 22.5 percent, respectively, compared to placebo. percent and 22.5

Trials 98

Trials Drugs FDA Approval Clinical Trials 98

XTalks

MARCH 25, 2024

The latest phase of Oprah’s weight loss journey brought her to GLP-1 receptor agonist drugs, which have taken Hollywood and social media by storm. GLP-1 receptor agonists, a class of drugs initially developed to treat type 2 diabetes, have been found to have significant effects on weight loss.

Drugs 105

Drugs Medicine Life Science Production 105

XTalks

OCTOBER 18, 2024

The US Food and Drug Administration (FDA) has approved Itovebi (inavolisib) for the treatment of adults with hormone receptor-positive (HR-positive), human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation.

HR 105

HR FDA Approval Hormones Compliance 105

XTalks

DECEMBER 5, 2024

Amgen announced positive results from a Phase II clinical trial evaluating its investigational obesity drug MariTide (maridebart cafraglutide, formerly AMG 133) for the treatment of obesity and overweight in both diabetic and non-diabetic patients. on Tuesday morning, the companys steepest fall in 23 years, according to Bloomberg.

Trials 104

Trials Drugs Clinical Trials Clinical Trials 104

XTalks

FEBRUARY 18, 2025

Insulin, a hormone produced by the pancreas, allows glucose to enter cells for energy. NovoLog and Novo Nordisks other rapid-acting insulin, Fiasp, is among some of the drugs up for price negotiations under the Inflation Reduction Act , with new pricing set to take effect at the beginning of next year.

Insulin 59

Insulin FDA Approval Production Hormones 59

XTalks

NOVEMBER 26, 2020

In addition to innovative new antibody drugs and mRNA vaccines, researchers have found that the sleep-regulating hormone melatonin may also offer protection against COVID-19. Lerner researchers developed a novel artificial intelligence platform to identify potential drugs for COVID-19, finding melatonin to be a promising candidate.

Research 98

Research Hormones Protein Regulation 98

XTalks

FEBRUARY 5, 2024

In the dynamic landscape of oncology therapeutics, understanding the trends and performances of leading drugs is crucial for stakeholders across the healthcare and life sciences sectors. Read on to learn more about the top 40 best-selling oncology drugs in 2023, based on 2022 sales data. mg capsules is $24,576.

FDA Approval 101

FDA Approval Drugs Sales Development 101

XTalks

MARCH 15, 2023

The US Food and Drug Administration (FDA) has issued warnings about the risk of abuse of amphetamine stimulants like Adderall, stating that use for “prolonged periods of time may lead to drug dependence and must be avoided.” The first generic versions of Strattera were approved in 2017 when the drug went off patent.

Drugs 98

Drugs Sales Trials Marketing 98

XTalks

NOVEMBER 9, 2022

Glucagon-like peptide-1 (GLP-1) receptor agonists are a newer class of diabetes drugs that have the potential to double as weight loss drugs, widening their lucrative market potentials. While weight loss effects can vary depending on the drug, studies show that all GLP-1 meds can result in an average weight loss of about 10.5

Insulin 98

Insulin Hormones FDA Approval Sales 98

XTalks

DECEMBER 5, 2024

Amgen announced positive results from a Phase II clinical trial evaluating its investigational obesity drug MariTide (maridebart cafraglutide, formerly AMG 133) for the treatment of obesity and overweight in both diabetic and non-diabetic patients. on Tuesday morning, the company’s steepest fall in 23 years, according to Bloomberg.

Trials 96

Trials Drugs Clinical Trials Clinical Trials 96

XTalks

JULY 19, 2024

Compounded GLP-1 medications, created by specialized pharmacies under a special US Food and Drug Administration (FDA) allowance due to ongoing shortage, have become increasingly popular for weight loss. The GLP-1 drug market is on its way to becoming one of the most lucrative pharmaceutical markets.

Pharmacy 104

Pharmacy Drugs Production Sales 104

XTalks

JANUARY 16, 2025

It is a complication of Graves disease, an immune system condition that causes the thyroid gland to make excess amounts of thyroid hormone. Thyroid eye disease affects an estimated 200,000 individuals in the US every year.

Trials 59

Trials Clinical Trials Clinical Trials Insulin 59

XTalks

JULY 17, 2024

Sweden-based biotech Camurus shared positive Phase III trial data for CAM2029, one of its lead candidates, in patients with the rare hormonal disorder acromegaly. Octreotide is a synthetic analog of somatostatin, a hormone in the body that inhibits the release of several other hormones, including growth hormone (GH), glucagon and insulin.

Trials 59

Trials Hormones Clinical Trials Clinical Trials 59

XTalks

NOVEMBER 5, 2024

Known for its innovative approach to GPCR drug discovery, Septerna leveraged its proprietary Native Complex Platform to establish a robust pipeline targeting endocrinology, immunology, inflammation and metabolic diseases. SEP-786, an oral parathyroid hormone 1 receptor (PTH1R) agonist, aims to restore essential mineral balance.

Drugs 59

Drugs Hormones Protein Antibody 59

XTalks

JULY 3, 2024

In March, Aligos announced the dosing of its first patient in its Phase IIa trial for a novel thyroid hormone receptor-beta agonist (ALG-055009) designed to address the root fibrosis of MASH. The drug is in the same class as Rezdiffra, which was approved this year as the first treatment for MASH.

Life Science 59

Life Science Hormones Vaccination Vaccine 59

XTalks

JUNE 5, 2023

Ozempic and Wegovy, which contain the active ingredient semaglutide, were approved by the US Food and Drug Administration (FDA). Semaglutide acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, mimicking the GLP-1 hormone released in the gastrointestinal tract after eating.

FDA Approval 98

FDA Approval Containment Drugs Pharmacy 98

XTalks

NOVEMBER 10, 2021

GlaxoSmithKline (GSK) unveiled positive safety and efficacy data for its oral anemia drug daprodustat from five pivotal trials for the drug last week. The drug was evaluated for the treatment of both dialysis and non-dialysis patients with anemia stemming from chronic kidney disease (CKD). percent for daprodustat and 10.5

Trials 97

Trials Hormones Drugs FDA Approval 97

XTalks

MARCH 8, 2021

Lilly and Novo are longtime competitors in the diabetes drug arena, particularly in the development of glucagon-like peptide-1 (GLP-1) receptor agonist drugs. GLP-1 receptor agonists mimic the action of GLP-1, an intestinal hormone that stimulates the secretion of insulin when blood glucose levels rise. cells in the pancreas.

Insulin 98

Insulin Hormones Clinical Trials Clinical Trials 98

pharmaphorum

JUNE 8, 2022

Zilebesiran (formerly ALN-AGT) is one of a new breed of gene-silencing drugs that are intended to treat common, chronic diseases with infrequent dosing to boost compliance with treatment. The post MHRA gives Alnylam ‘innovation passport’ for hypertension drug zilebesiran appeared first on.

Gene Silencing 52

Gene Silencing Drugs Medicine Regulation 52

XTalks

SEPTEMBER 6, 2024

Lutathera is used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut and hindgut. Nevertheless, Novartis still believes the drug is on track to achieving blockbuster status.

Development 105

Development Manufacturing Marketing Hormones 105

XTalks

NOVEMBER 3, 2022

Eli Lilly is finding itself in an enviable position with its newly launched diabetes injection Mounjaro (tirzepatide) and blockbuster diabetes med Trulicity due to temporary shortages of competitor Novo Nordisk’s diabetes drug Ozempic (semaglutide). Lilly is also looking to pitch Mounjaro as an obesity drug and directly take on Novo’s Wegovy.

Sales 98

Sales FDA Approval Production Insulin 98

pharmaphorum

NOVEMBER 27, 2022

Incidents such as the hormone replacement therapy drug shortage in early 2022 have shown the damaging impact supply chain issues can have on people who depend on these drugs. Mix ups in hand-offs are another large disruptor, especially when drugs have specific shipping requirements. Automation can be such a solution.

Production 105

Production Manufacturing Drugs Marketing 105

XTalks

MARCH 13, 2024

Related: Transforming Eye Care: Innovating New Glaucoma and Dry Eye Disease Treatments — Featuring Pierre Simon, VP Marketing, Sight Sciences – Xtalks Life Science Podcast Ep. One example is Glaukos’ iDose TR , an intracameral implant designed to provide continuous drug therapy inside the eye for up to three years.

Gene Therapy 111

Gene Therapy Gene Life Science DNA 111

XTalks

SEPTEMBER 17, 2020

Surrogate endpoints were used as the basis for approval of 45 percent of new drugs reviewed by the FDA between 2010 and 2012. For example, studies of heart attack prevention medications use the surrogate endpoint of low-density lipoprotein cholesterol (LDL-C) to assess the effectiveness of new drugs. What Is a Surrogate Endpoint?

Trials 98

Trials Gene Hormones Clinical Trials 98

XTalks

JULY 26, 2024

The US Food and Drug Administration (FDA) has given the green light to Femlyv , a combination oral contraceptive containing norethindrone acetate and ethinyl estradiol. Norethindrone acetate and ethinyl estradiol are legacy drugs that have been approved since 1968 in a swallowable tablet form for the prevention of pregnancy.

FDA Approval 52

FDA Approval Hormones Containment Drugs 52